<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00118846</url>
  </required_header>
  <id_info>
    <org_study_id>U01AT001653</org_study_id>
    <secondary_id>U01AT001653</secondary_id>
    <secondary_id>U01AT001653-02S2</secondary_id>
    <secondary_id>U01AT001653-02S4</secondary_id>
    <secondary_id>U01AT001653-02S5</secondary_id>
    <nct_id>NCT00118846</nct_id>
  </id_info>
  <brief_title>Women's Isoflavone Soy Health (WISH) Trial</brief_title>
  <official_title>Phytoestrogens and Progression of Atherosclerosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Southern California</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Center for Complementary and Integrative Health (NCCIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Office of Dietary Supplements (ODS)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Office of Research on Women's Health (ORWH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Solae, LLC</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Southern California</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether soy supplements can reduce hardening of the
      arteries in postmenopausal women. This study will also determine the effects of soy
      supplements on mental processes, bone mineral density, and breast tissue density.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Heart disease is the leading cause of death among women in the United States.
      Atherosclerosis, a primary cause of heart disease, accounts for more than 485,000 heart
      attacks and 370,000 strokes each year in American women. Data indicate that a woman's risk of
      suffering from an atherosclerosis-related cardiovascular event significantly increases after
      menopause; this risk may be due to reduced estrogen production associated with menopause. Soy
      isoflavones are plant compounds that are structurally similar to human estrogen. Evidence
      suggests that soy supplements may provide the same protection against heart disease as
      estrogen in postmenopausal women. This study will determine the effects of soy supplements on
      atherosclerosis progression, cognition, bone mineral density, and breast tissue density
      changes in postmenopausal women.

      This study will last 2.5 years. Participants will be randomly assigned to receive either soy
      supplements or placebo daily for the duration of the study.

      The active product, which will be given as two divided doses, is 25 g soy protein containing
      85 mg aglycone weight naturally-occurring isoflavones (150 mg total isoflavone), genistein 45
      mg aglycone weight (80 mg total weight), daidzein 35 mg aglycone weight (60 mg total weight)
      and glycitein 5 mg aglycone weight (10 mg total weight). Blood collection, cognitive tests,
      and mammograms will be used to assess participants at study entry, at each monthly visit, and
      at study completion.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2004</start_date>
  <completion_date type="Actual">March 2009</completion_date>
  <primary_completion_date type="Actual">September 2005</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression of subclinical atherosclerosis measured by the rate of change in distal common carotid artery far wall intima-media thickness in computer image processed B-mode ultrasonograms</measure>
    <time_frame>Baseline and every 6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Longitudinal change in cognitive function, bone mineral density, and mammographic percent density</measure>
    <time_frame>Cognitive function: Baseline and end-of-study; Bone mineral density: Baseline, 12 month, 30 month; Mammographic percent density: Baseline, 12 month, 24 month</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">350</enrollment>
  <condition>Atherosclerosis</condition>
  <condition>Cardiovascular Diseases</condition>
  <condition>Heart Diseases</condition>
  <condition>Osteoporosis</condition>
  <condition>Menopause</condition>
  <condition>Breast Cancer</condition>
  <condition>Dementia</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>25 gm soy protein administered twice daily in equivalent dosages (12.5 gm)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>25 g soy protein supplement</intervention_name>
    <description>25 g soy protein admisitered in equally divided dosage twice daily</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Matching placebo</intervention_name>
    <description>Milk protein administered twice daily</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Postmenopausal, defined as having no vaginal bleeding for at least 1 year and having a
             serum estradiol level higher than 20 pg/ml

        Exclusion Criteria:

          -  Signs or history of cardiovascular disease

          -  Diabetes mellitus or fasting serum glucose of 140 mg/dL or greater

          -  Plasma triglyceride levels of 500 mg/dL or greater

          -  Serum creatinine greater than 2.0 mg/dL

          -  Uncontrolled hypertension

          -  Untreated thyroid disease

          -  Life expectancy less than 5 years

          -  Current use of hormone replacement therapy (HRT)

          -  Soy- or nut-related food allergies

          -  Follow a vegan diet
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Howard N. Hodis, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Southern California Keck School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Southern California Keck School of Medicine</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 7, 2005</study_first_submitted>
  <study_first_submitted_qc>July 7, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 12, 2005</study_first_posted>
  <last_update_submitted>March 28, 2017</last_update_submitted>
  <last_update_submitted_qc>March 28, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 30, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Southern California</investigator_affiliation>
    <investigator_full_name>Howard Hodis</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Women</keyword>
  <keyword>Complementary and Alternative Medicine</keyword>
  <keyword>CAM</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Dementia</mesh_term>
    <mesh_term>Osteoporosis</mesh_term>
    <mesh_term>Atherosclerosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

